Literature DB >> 12228192

Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine.

Yasuhiro Masubuchi1, Atsushi Ose, Toshiharu Horie.   

Abstract

Incubation of human liver microsomes with diclofenac in the presence of NADPH resulted in a decrease in testosterone 6 beta-hydroxylation activity. The decrease in the activity followed time- and concentration-dependent kinetics, required oxidative metabolism, and was resistant to reduced glutathione, suggesting that diclofenac causes a mechanism-based inactivation of cytochrome p450 (p450) 3A4 (CYP3A4). The inactivation was reproduced by using microsomes from B-lymphoblastoid cell lines expressing CYP3A4 instead of human liver microsomes. No other monooxygenase activities measured as indexes of p450 enzymes; CYP2C8, CYP2C9, or CYP2C19 was inactivated by the same incubation procedure. Quinidine, a stimulant of CYP3A4-mediated diclofenac 5-hydroxylation, did not affect the inactivation of CYP3A4 assessed by testosterone 6 beta-hydroxylation activity but accelerated the inactivation assessed by diazepam 3-hydroxylation activity. These results supported the idea that diclofenac 5-hydroxylation is involved in the inactivation of CYP3A4 and described for the first time a stimulation of mechanism-based inactivation attributable to CYP3A4 heterotropic cooperativity. Preincubation of human liver microsomes with 5-hydroxydiclofenac instead of diclofenac did not cause the inactivation of CYP3A4, suggesting that 5-hydroxydiclofenac is not a precursor of a postulated reactive metabolite that inactivates CYP3A4, and thus 5-hydroxylation step is critical to inactivation of CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228192     DOI: 10.1124/dmd.30.10.1143

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.

Authors:  Chii Chii Chew; Salby Ng; Yun Lee Chee; Teng Wai Koo; Ming Hui Liew; Evelyn Li-Ching Chee; Pilar Modamio; Cecilia Fernández; Eduardo L Mariño; Ignacio Segarra
Journal:  Invest New Drugs       Date:  2017-03-11       Impact factor: 3.850

2.  Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.

Authors:  Jian Ren Tan; Srikumar Chakravarthi; John Paul Judson; Nagaraja Haleagrahara; Ignacio Segarra
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-05       Impact factor: 3.000

Review 3.  The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Authors:  Brooke M VandenBrink; Nina Isoherranen
Journal:  Curr Opin Drug Discov Devel       Date:  2010-01

4.  Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.

Authors:  Yunfeng Tie; Brooks McPhail; Huixiao Hong; Bruce A Pearce; Laura K Schnackenberg; Weigong Ge; Dan A Buzatu; Jon G Wilkes; James C Fuscoe; Weida Tong; Bruce A Fowler; Richard D Beger; Eugene Demchuk
Journal:  Molecules       Date:  2012-03-15       Impact factor: 4.411

5.  Hyaluronan-Loaded Liposomal Dexamethasone-Diclofenac Nanoparticles for Local Osteoarthritis Treatment.

Authors:  Ming-Cheng Chang; Ping-Fang Chiang; Yu-Jen Kuo; Cheng-Liang Peng; Kuan-Yin Chen; Ying-Cheng Chiang
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

6.  Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes.

Authors:  Suzan Wopereis; Carina M Rubingh; Marjan J van Erk; Elwin R Verheij; Trinette van Vliet; Nicole H P Cnubben; Age K Smilde; Jan van der Greef; Ben van Ommen; Henk F J Hendriks
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

7.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Authors:  Shufeng Zhou; Eli Chan; Xiaotian Li; Min Huang
Journal:  Ther Clin Risk Manag       Date:  2005-03       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.